Can these things cure us? How leaders are tackling health issues in Miami
These articles focus on innovative approaches to tackling health issues in Miami through community engagement, partnerships and technology.
A new partnership involving electric cars aims to improve accessibility to prenatal and postpartum care in South Florida, addressing transportation challenges for pregnant women. To address Alzheimer's research, University of Miami researchers venture into local communities. Technology's role in health care receives attention as well. Innovations like high-intensity ultrasounds offer non-invasive cancer treatments at Memorial Healthcare System. Meanwhile, gene therapy at Jackson Health shows promise in alleviating symptoms of sickle cell disease, changing patient lives dramatically.
Read the stories below to catch up.
Marie Odvil uses a free car service for low-income pregnant mothers provided by Green Cars For Kids in partnership with Freebee and Jackson Health on Wednesday, Aug. 28, 2024, outside of Holtz Children's Hospital on Jackson's campus in Miami. By Alie Skowronski
NO. 1: CAN A CAR RIDE HELP YOUR HEALTH? FOR SOUTH FLORIDA MATERNITY PATIENTS, IT'S AN ISSUE
What to know about the transit services for mother and baby. | Published October 7, 2024 | Read Full Story by Michelle Marchante
A caretaker, center, offers cafecito to Asustina Valdes Cabrera, left, while she is tested by UHealth medical researcher Dr. Katrina Celis, right, as part of an Alzheimer study during a community outreach event for the John P. Hussman Institute for Human Genomics where UM researchers performed tests, enrolled new participants and took blood samples to a new Biorespository opening at UHealth's campus, at Hora Feliz Adult Day Care on Thursday, January 16, 2025, in Hialeah, Fla. By D.A. Varela
NO. 2: HOW A UM LAB IS UNLOCKING THE SECRETS OF THE BRAIN. IT STARTS WITH A PERSONAL MESSAGE
What to know about the visits. | Published January 24, 2025 | Read Full Story by Michelle Marchante
No image found Dr. Omar H. Llaguna, specialist in surgical oncology, looks at a medium that mimics a liver tumor in a human body to demonstrate how a histotripsy procedure works, performed by a HistoSonics medical device during a demonstration at the Memorial Hospital West, in Pembroke Pines, on Thursday June 12, 2025. By Pedro Portal
NO. 3: 'LIFE JUST CHANGED.' HOW MIAMI DOCTORS USE TECH TO TREAT CANCER AND SICKLE CELL
What to know about new ultrasound, editing genes and prosthetics. | Published June 19, 2025 | Read Full Story by Michelle Marchante
No image found Dr. Juan Cendan, dean of FIU's Herbert Wertheim College of Medicine, speaks during a ceremony announcing the launch of a new clinical, research and academic collaboration between FIU and Nicklaus Children's Health System on Monday, May 19, 2025, at Florida International University campus in Miami, Fla. By Alie Skowronski
NO. 4: WHAT A UNIVERSITY AND HOSPITAL PARTNERSHIP MEANS FOR HEALTHCARE IN MIAMI
Here are five takeaways. | Published May 22, 2025 | Read Full Story by Miami Herald Archive, with AI summarization
The summary above was drafted with the help of AI tools and edited by journalists in our News division. All stories listed were reported, written and edited by McClatchy journalists.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Magazine
2 hours ago
- Time Magazine
The Issue with Living Longer
We're living longer than ever—but those extra years aren't unfolding the way many hoped. Instead of later years spent thriving, millions are instead facing chronic illness, cognitive decline, and financial strain. As of July 2025, the estimated global average life expectancy is approximately 73.5 years. This represents a slight increase from previous years, continuing a long-term trend of rising longevity (despite a temporary dip due to the COVID-19 pandemic). High-income countries with advanced healthcare systems, good sanitation, and healthy lifestyles have an even longer life expectancy average, reaching up to 84 years. Our lifespans have expanded, but our healthspans—the number of years we live with mental sharpness, physical independence, and emotional well-being—has not kept pace. If we don't prepare now, the result won't just be personal hardship. It will reshape families, erode legacies, and overwhelm the caregiving systems we all depend on. For much of the modern era, societies structured life around a four-stage model: youth, family-building, work, and a relatively short retirement. That framework no longer reflects reality. We now live through five distinct life segments, two of which—mid-life caregiving and prolonged dependency in later years—are stretching families, economies, and communities in entirely new ways. The modern life course now looks more like this: The shift from four to five segments may seem incremental, but the consequences are profound. Mid-life adults are being pulled in multiple directions, often while navigating dual-income households or living alone. Retirement, once a brief final chapter, can now stretch 20 to 30 years, and too often, those years are marked by rising dependency. Systems of support—social, economic, and medical—are struggling to keep up. What's emerging is a global healthspan gap, where we're living longer but not necessarily living well. The healthspan gap—and what it costs Research suggests that we're entering the largest intergenerational wealth transfer in history, with trillions expected to pass from older to younger generations. But much of that wealth may never arrive. Long-term care costs—especially when not covered by insurance or public programs—can quickly erode assets. Just a few years of residential or home-based care can deplete savings accumulated over a lifetime. Many families face these costs without adequate safety nets, and in aging societies, public eldercare systems are under mounting financial pressure. If fiscal tightening leads to austerity-driven cutbacks, families may shoulder even more of the burden—quietly draining the legacies they hoped to pass on. We're not just living longer—we're also living longer with dementia, Alzheimer's, and other forms of cognitive impairment. And without meaningful action, this trajectory could accelerate. This is not a dystopian fantasy. It's a tangible future scenario if healthspan continues to lag behind lifespan, and our support systems fail to evolve. The healthspan imperative If we want longer lives to truly become better lives, we must shift our focus from simply extending lifespan to improving healthspan. That requires new thinking in prevention, technology, policy, and planning. First, we must prioritize prevention and delay—not just in old age, but across all stages of life. Expanding access to community-based wellness programs focused on movement, nutrition, and connection can promote healthier aging. Preventive care must start earlier and before symptoms emerge, with lifelong attention to cognitive and emotional health. Supporting flexible work and phased retirement can reduce stress on caregivers in their peak working years. Second, technology is a powerful enabler. AI assistants and care robots can assist with mobility, medication reminders, and safety monitoring to help older adults remain independent longer. In parenting, tech is already expanding: AI tutors and robotic companions support learning in dual-income or single-parent households. Predictive tools and remote monitoring systems can detect early signs of decline – whether cognitive, physical or emotional – and trigger timely intervention. These tools don't replace human care. They extend it by enhancing independence, extending capabilities, and reducing caregiver stress. Our public systems must also evolve. Governments should shift more funding from institutional care to proactive, community-based models. Policies that support aging in place, expand caregiver tax credits, and create savings incentives for long-term care can align care with reality—especially as aging populations strain public budgets. Finally, we must plan across generations. Families need support to discuss roles, responsibilities, and expectations before a crisis hits. Healthspan should be integrated into financial and estate planning, because how long we live well directly affects what we leave behind. Caregiving, aging, and inheritance are not separate life challenges, but parts of a shared human journey that requires input and support from all those involved. We stand at a global inflection point. If we let longevity unfold without intention, we risk decades of dependency, fragmented families, and generational loss. But if we choose to invest in healthspan—early, equitably, and boldly—we can reshape the future. We can protect the well-being of aging populations without sacrificing the financial and emotional security of younger generations. We can use innovation not just to extend life, but to enrich it. And we can build communities that grow older with strength, grace, and resilience. We've already added years to life. Now it's time to add life to those years.
Yahoo
19 hours ago
- Yahoo
World Brain Day: brain health and an ageing population
World Brain Day, celebrated annually on 22 July, serves as a call to action for increased neurological health awareness and advocacy. In the context of a rapidly ageing global population, the burden of neurodegenerative diseases such as Alzheimer's and Parkinson's disease is rising, posing significant challenges to healthcare systems. These progressive disorders not only diminish quality of life, but also contribute substantially to disability and dependency among older adults. Apart from posing a public health concern, they pose personal issues affecting individuals and families, and contribute to long-term care needs among the elderly, both for professional and informal care. These diseases erode memory and independence, and often lead to emotional and physical hardship for patients and families. Cases of Alzheimer's disease and Parkinson's disease (PD) are increasing globally. Several factors are contributing to the increasing prevalence of Alzheimer's and PD. These included the ageing population and increased detection and diagnosis. GlobalData's Alzheimer's and PD epidemiology forecasts shed light on the future burden of these diseases. The latest report forecasts an increase in the diagnosed prevalent cases of Alzheimer's in the eight major markets (8MM: China, France, Germany, Italy, Japan, Spain, the UK and the US) from approximately 11 million in 2025 to more than 12.3 million in 2028. Diagnosed prevalent cases of PD are expected to increase from 2.7 million cases in 2025 to 3.1 million cases in 2033 in the seven major markets (7MM: France, Germany, Italy, Japan, Spain, the UK and the US). Understanding the key risk factors and potential challenges of managing these diseases will help healthcare providers and patients recognise symptoms earlier, which could slow disease progression, understand individual risk factors, and coordinate care among different health professionals, such as neurologists, primary care providers and caregivers. With global life expectancy rising, the at-risk population for Alzheimer's and PD will grow. Awareness days can help educate people on professional and self-administered screening tools for signs of memory and cognitive impairment related to Alzheimer's, such as the Mini-Mental State Examination (MMSE) and Mini-Cog (administered by professionals), and the self-administered test called SAGE (the Self-Administered Gerocognitive Exam). In the case of PD, events such as World Brain Day can shed light on symptoms such as tremors, stiffness and slow movement. Awareness days draw attention to diseases. They advance global notice, understanding and diagnosis. By spotlighting brain health on an international stage, the campaign encourages collaboration among researchers, clinicians and policymakers to address gaps in access to care and treatment. This is important when we consider that Alzheimer's and PD are major challenges in an ageing world. "World Brain Day: brain health and an ageing population" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
19 hours ago
- Business Upturn
Dementia Associated with Alzheimer's Disease Drug Development Surges with 180+ Companies Pushing New Therapeutic Frontiers
By GlobeNewswire Published on July 17, 2025, 22:00 IST New York, USA, July 17, 2025 (GLOBE NEWSWIRE) — Dementia Associated with Alzheimer's Disease Drug Development Surges with 180+ Companies Pushing New Therapeutic Frontiers | DelveInsight Dementia associated with Alzheimer's disease is a progressive neurodegenerative condition characterized by memory loss, cognitive decline, and impaired daily functioning. The growing aging population worldwide is leading to a rising prevalence of Alzheimer's-related dementia, fueling demand for effective diagnostics and disease-modifying therapies. DelveInsight's 'Dementia Associated with Alzheimer's Disease Pipeline Insight 2025' report provides comprehensive global coverage of pipeline dementia associated with Alzheimer's disease therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the dementia associated with Alzheimer's disease pipeline domain. Key Takeaways from the Dementia Associated with Alzheimer's Disease Pipeline Report DelveInsight's dementia associated with Alzheimer's disease pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline dementia associated with Alzheimer's disease drugs. active players working to develop pipeline dementia associated with Alzheimer's disease drugs. Key dementia associated with Alzheimer's disease companies such as BioVie, Bristol Myers Squibb, Cognition Therapeutics, TrueBinding, KeyMed Biosciences, Alzinova, AriBio Co., Ltd., Cognition Therapeutics, AbbVie Inc., Allyx Therapeutics, Inc., Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Amylyx Pharmaceuticals Inc. , Merry Life Biomedical Company , Praxis Bioresearch, Alector, Inc., Galimedix, MIRAMOON Pharma, NervGen Pharma, Psy Therapeutics, NW PharmaTech, PerioTrap Pharmaceuticals, ADEL, Inc., TauRx Therapeutics Ltd, Eli Lilly and Company, Suven Life Sciences, AB Science, Neurim Pharmaceuticals, Merck Sharp & Dohme, Novartis, Priavoid, Pharmazz, Partner Therapeutics, UCB Biopharma, Longeveron Inc., and others are evaluating new dementia associated with Alzheimer's disease drugs to improve the treatment landscape. and others are evaluating new dementia associated with Alzheimer's disease drugs to improve the treatment landscape. Promising pipeline dementia associated with Alzheimer's disease therapies, such as Bezisterim KarXT, CT-1812, TB 006, CM383, ALZ 101, AR1001, CT1812, ABBV-916, ALX-001, E2814, VT301, AMX0035, TML-6, PRX-P4-003, ADP037-ABC, GAL-201, MP-010, NVG 300, PSY-02, EMCBD-1, S-636, ADEL-Y07, TRx0237, Remternetug, Masupirdine, Masitinib, Piromelatine, MK-1167, Siponimod, PRI-002, PMZ-1620, Sargramostim, Bepranemab, Lomecel-B, and others, are in different phases of Dementia Associated with Alzheimer's Disease clinical trials. and others, are in different phases of Dementia Associated with Alzheimer's Disease clinical trials. In May 2025, Nuravax Inc. was awarded a USD 3 million grant from the National Institutes of Health (NIH) to support Duvax, the first dual-target Alzheimer's vaccine, in its entry into human clinical trials. was awarded a USD 3 million grant from the National Institutes of Health (NIH) to support Duvax, the first dual-target Alzheimer's vaccine, in its entry into human clinical trials. In February 2025, NKGen Biotech, Inc . announced that the US Food and Drug Administration had granted Fast Track designation for the investigation of troculeucel, ex vivo expanded autologous NK cell therapy, for the treatment of moderate Alzheimer's disease. . announced that the US Food and Drug Administration had granted Fast Track designation for the investigation of troculeucel, ex vivo expanded autologous NK cell therapy, for the treatment of moderate Alzheimer's disease. In February 2025, Swedish pharmaceutical company AlzeCure Pharma secured a Eur 2.5m (USD 2.62m) grant from the EU's European Innovation Council (EIC) to support a Phase IIa trial of NeuroRestore ACD856 for Alzheimer's disease. Swedish pharmaceutical company AlzeCure Pharma secured a Eur 2.5m (USD 2.62m) grant from the EU's European Innovation Council (EIC) to support a Phase IIa trial of NeuroRestore ACD856 for Alzheimer's disease. In April 2025, Biogen announced that the US Food and Drug Administration had granted Fast Track designation to BIIB080 , an investigational antisense oligonucleotide (ASO) therapy targeting tau, for the treatment of Alzheimer's disease. announced that the US Food and Drug Administration had granted Fast Track designation to , an investigational antisense oligonucleotide (ASO) therapy targeting tau, for the treatment of Alzheimer's disease. In March 2025, Longeveron Inc. announced the positive outcome of a Type B meeting with the US Food and Drug Administration, supporting the advancement of laromestrocel (Lomecel-BTM), a proprietary, scalable, allogeneic, investigational cellular therapy, as a potential treatment for Alzheimer's disease. The Company and the FDA reached foundational alignment on the overall study design for a proposed single, pivotal, seamless adaptive Phase II/III clinical trial, including proposed AD patient population, proposed placebo control, laromestrocel (Lomecel-BTM) dose selection and frequency, trial duration, and trial endpoints. To accelerate the pathway to potential approval, the FDA agreed to consider a BLA based on positive interim trial results from the planned single study. announced the positive outcome of a Type B meeting with the US Food and Drug Administration, supporting the advancement of laromestrocel (Lomecel-BTM), a proprietary, scalable, allogeneic, investigational cellular therapy, as a potential treatment for Alzheimer's disease. The Company and the FDA reached foundational alignment on the overall study design for a proposed single, pivotal, seamless adaptive Phase II/III clinical trial, including proposed AD patient population, proposed placebo control, laromestrocel (Lomecel-BTM) dose selection and frequency, trial duration, and trial endpoints. To accelerate the pathway to potential approval, the FDA agreed to consider a BLA based on positive interim trial results from the planned single study. In February 2025, Neuphoria Therapeutics announced that the company was due to receive a USD 15 million milestone payment from Merck, known as MSD outside the United States and Canada. The payment was triggered by the initiation, by Merck, of a Phase II clinical trial to evaluate the safety and efficacy of MK-1167, an α7 nicotinic acetylcholine receptor positive allosteric modulator (PAM), for the treatment of the symptoms of Alzheimer's disease dementia. announced that the company was due to receive a USD 15 million milestone payment from Merck, known as MSD outside the United States and Canada. The payment was triggered by the initiation, by Merck, of a Phase II clinical trial to evaluate the safety and efficacy of MK-1167, an α7 nicotinic acetylcholine receptor positive allosteric modulator (PAM), for the treatment of the symptoms of Alzheimer's disease dementia. In February 2025, NKGen Biotech announced that the US Food and Drug Administration has granted Fast Track designation for the investigation of troculeucel , ex vivo expanded autologous NK cell therapy, for the treatment of moderate Alzheimer's disease. announced that the US Food and Drug Administration has granted Fast Track designation for the investigation of , ex vivo expanded autologous NK cell therapy, for the treatment of moderate Alzheimer's disease. In February 2025, NeuroTherapia, Inc., a clinical-stage company focused on developing oral therapies for neurodegenerative diseases, announced it had received approval for its Phase II clinical trial from the European Medicines Agency (EMA). NTRX-07, the company's lead molecule, will be administered to Alzheimer's disease (AD) participants for 28 days in this double-masked, randomized clinical trial. In addition to monitoring safety, pharmacokinetics, and standard measures of clinical efficacy (ADAS-cog, MMSA, and Trails Making Test), the trial is also designed to give an indication of target engagement by analyzing various biomarkers of neuroinflammation and neuronal function. a clinical-stage company focused on developing oral therapies for neurodegenerative diseases, announced it had received approval for its Phase II clinical trial from the European Medicines Agency (EMA). NTRX-07, the company's lead molecule, will be administered to Alzheimer's disease (AD) participants for 28 days in this double-masked, randomized clinical trial. In addition to monitoring safety, pharmacokinetics, and standard measures of clinical efficacy (ADAS-cog, MMSA, and Trails Making Test), the trial is also designed to give an indication of target engagement by analyzing various biomarkers of neuroinflammation and neuronal function. In January 2025, the US FDA granted Fast Track designation to Posdinemab , a phosphorylated tau-directed monoclonal antibody (mAb) being investigated to treat patients with early Alzheimer's disease. the US FDA granted Fast Track designation to , a phosphorylated tau-directed monoclonal antibody (mAb) being investigated to treat patients with early Alzheimer's disease. In November 2024 , Alector announced results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease (AD). , announced results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease (AD). In October 2024, Hoth Therapeutics, Inc. announced the granting of a US patent for its pioneering Alzheimer's treatment, HT-ALZ. Request a sample and discover the recent advances in dementia associated with Alzheimer's disease drugs @ Dementia Associated with Alzheimer's Disease Pipeline Report The dementia associated with Alzheimer's disease pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage dementia associated with Alzheimer's disease drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the dementia associated with Alzheimer's disease clinical trial landscape. Dementia Associated with Alzheimer's Disease Overview Dementia is a broad term that refers to a marked decline in cognitive abilities that affects a person's daily functioning. Alzheimer's disease (AD) is the most common form of dementia, responsible for at least two-thirds of cases in people aged 65 and older. AD is a progressive neurodegenerative disorder that begins gradually and leads to worsening impairments in behavior and cognitive skills such as memory, understanding, language, attention, reasoning, and judgment. Although Alzheimer's itself is not directly fatal, it greatly increases the risk of other complications that can ultimately result in death. The diagnosis of Alzheimer's-related dementia usually requires a thorough evaluation, including medical history, cognitive assessments, physical and neurological exams, and sometimes brain imaging. Physicians first exclude other possible causes of cognitive decline, like vitamin deficiencies or thyroid issues. Cognitive tests evaluate memory, problem-solving, and language to identify patterns indicative of Alzheimer's. Brain scans, such as MRI or CT, help detect structural changes like brain shrinkage. More advanced diagnostic tools, including PET scans or cerebrospinal fluid tests, can reveal specific biomarkers linked to Alzheimer's, offering stronger confirmation. Currently, there is no cure for Alzheimer's disease since brain cell loss cannot be reversed. However, treatments are available to ease symptoms and enhance the quality of life for patients and their caregivers. Cholinesterase inhibitors are medications that help reduce cognitive symptoms such as memory problems, confusion, and impaired judgment by improving communication between brain cells and slowing symptom progression. The three FDA-approved drugs commonly used for Alzheimer's treatment include donepezil (Aricept) for all stages, and galantamine (Razadyne) and rivastigmine (Exelon) for mild to moderate stages. Find out more about dementia associated with Alzheimer's disease drugs @ Dementia Associated with Alzheimer's Disease Treatment A snapshot of the Pipeline Dementia Associated with Alzheimer's Disease Drugs mentioned in the report: Drugs Company Phase MoA RoA Bezisterim (NE3107) BioVie III NF-kappa B inhibitor; Tumour necrosis factor inhibitor Oral KarXT Bristol Myers Squibb III Muscarinic M1 receptor agonists; Muscarinic M4 receptor agonists; Muscarinic receptor antagonists Oral Buntanetap Annovis Bio III Alpha-synuclein inhibitors; Amyloid beta-protein precursor inhibitors; HD protein inhibitors; Tau protein inhibitors Oral AR1001 AriBio III Type 5 cyclic nucleotide phosphodiesterase inhibitors Oral CT-1812 Cognition Therapeutics II Sigma-2 receptor antagonists Oral TW001 Treeway B.V. II Antioxidants; Free radical scavengers Oral AMX0035 Amylyx Pharmaceuticals II Ammonia scavenger; Histone deacetylase inhibitor; Phosphotransferase inhibitor Oral CM383 KeyMed Biosciences I Amyloid beta-protein inhibitors Intravenous Learn more about the emerging dementia associated with Alzheimer's disease therapies @ Dementia Associated with Alzheimer's Disease Clinical Trials Dementia Associated with Alzheimer's Disease Therapeutics Assessment The dementia associated with Alzheimer's disease pipeline report proffers an integral view of the emerging dementia associated with Alzheimer's disease therapies segmented by stage, product type, molecule type, route of administration, and mechanism of action. Scope of the Dementia Associated with Alzheimer's Disease Pipeline Report Coverage : Global : Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical Oral, Intravenous, Subcutaneous, Parenteral, Topical Therapeutics Assessment By Molecule Type : Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy : Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy Therapeutics Assessment By Mechanism of Action : Adiponectin stimulants, Interleukin 23 inhibitors, Interleukin 6 inhibitors, Mitogen-activated protein kinase 1 inhibitors, Mitogen-activated protein kinase 3 inhibitors, NF-kappa B inhibitors, Tumour necrosis factor inhibitors, Muscarinic M1 receptor agonists, Muscarinic M4 receptor agonists, Muscarinic receptor antagonists, Microfilament protein modulators, Sigma-2 receptor antagonists, Amyloid beta-protein inhibitors, TREM2 protein-stimulants, Type 5 cyclic nucleotide phosphodiesterase inhibitors, Ammonia scavengers, Histone deacetylase inhibitors, Phosphotransferase inhibitors : Adiponectin stimulants, Interleukin 23 inhibitors, Interleukin 6 inhibitors, Mitogen-activated protein kinase 1 inhibitors, Mitogen-activated protein kinase 3 inhibitors, NF-kappa B inhibitors, Tumour necrosis factor inhibitors, Muscarinic M1 receptor agonists, Muscarinic M4 receptor agonists, Muscarinic receptor antagonists, Microfilament protein modulators, Sigma-2 receptor antagonists, Amyloid beta-protein inhibitors, TREM2 protein-stimulants, Type 5 cyclic nucleotide phosphodiesterase inhibitors, Ammonia scavengers, Histone deacetylase inhibitors, Phosphotransferase inhibitors Key Dementia Associated with Alzheimer's Disease Companies : BioVie, Bristol Myers Squibb, Cognition Therapeutics, TrueBinding, KeyMed Biosciences, Alzinova, AriBio Co., Ltd., Cognition Therapeutics, AbbVie Inc., Allyx Therapeutics, Inc., Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Amylyx Pharmaceuticals Inc., Merry Life Biomedical Company, Praxis Bioresearch, Alector, Inc., Galimedix, MIRAMOON Pharma, NervGen Pharma, Psy Therapeutics, NW PharmaTech, PerioTrap Pharmaceuticals, ADEL, Inc., TauRx Therapeutics Ltd, Eli Lilly and Company, Suven Life Sciences, AB Science, Neurim Pharmaceuticals, Merck Sharp & Dohme, Novartis, Priavoid, Pharmazz, Partner Therapeutics, UCB Biopharma, Longeveron Inc., and others. : BioVie, Bristol Myers Squibb, Cognition Therapeutics, TrueBinding, KeyMed Biosciences, Alzinova, AriBio Co., Ltd., Cognition Therapeutics, AbbVie Inc., Allyx Therapeutics, Inc., Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Amylyx Pharmaceuticals Inc., Merry Life Biomedical Company, Praxis Bioresearch, Alector, Inc., Galimedix, MIRAMOON Pharma, NervGen Pharma, Psy Therapeutics, NW PharmaTech, PerioTrap Pharmaceuticals, ADEL, Inc., TauRx Therapeutics Ltd, Eli Lilly and Company, Suven Life Sciences, AB Science, Neurim Pharmaceuticals, Merck Sharp & Dohme, Novartis, Priavoid, Pharmazz, Partner Therapeutics, UCB Biopharma, Longeveron Inc., and others. Key Dementia Associated with Alzheimer's Disease Pipeline Therapies: Bezisterim KarXT, CT-1812, TB 006, CM383, ALZ 101, AR1001, CT1812, ABBV-916, ALX-001, E2814, VT301, AMX0035, TML-6, PRX-P4-003, ADP037-ABC, GAL-201, MP-010, NVG 300, PSY-02, EMCBD-1, S-636, ADEL-Y07, TRx0237, Remternetug, Masupirdine, Masitinib, Piromelatine, MK-1167, Siponimod, PRI-002, PMZ-1620, Sargramostim, Bepranemab, Lomecel-B, and others. Dive deep into rich insights for new dementia associated with Alzheimer's disease treatments, visit @ Dementia Associated with Alzheimer's Disease Drugs Table of Contents 1. Dementia Associated with Alzheimer's Disease Pipeline Report Introduction 2. Dementia Associated with Alzheimer's Disease Pipeline Report Executive Summary 3. Dementia Associated with Alzheimer's Disease Pipeline: Overview 4. Analytical Perspective In-depth Commercial Assessment 5. Dementia Associated with Alzheimer's Disease Clinical Trial Therapeutics 6. Dementia Associated with Alzheimer's Disease Pipeline: Late-Stage Products (Pre-registration) 7. Dementia Associated with Alzheimer's Disease Pipeline: Late-Stage Products (Phase III) 8. Dementia Associated with Alzheimer's Disease Pipeline: Mid-Stage Products (Phase II) 9. Dementia Associated with Alzheimer's Disease Pipeline: Early-Stage Products (Phase I) 10. Dementia Associated with Alzheimer's Disease Pipeline Therapeutics Assessment 11. Inactive Products in the Dementia Associated with Alzheimer's Disease Pipeline 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Key Companies 14. Key Products in the Dementia Associated with Alzheimer's Disease Pipeline 15. Unmet Needs 16. Market Drivers and Barriers 17. Future Perspectives and Conclusion 18. Analyst Views 19. Appendix For further information on the dementia associated with Alzheimer's disease pipeline therapeutics, reach out @ Dementia Associated with Alzheimer's Disease Therapeutics Related Reports Alzheimer's Disease Epidemiology Alzheimer's Disease Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted Alzheimer's disease epidemiology in the 7MM, i.e., the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. Alzheimer's Disease Market Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alzheimer's disease companies, including BioVie, AB Science, Cassava Sciences, TauRx Therapeutics, Novo Nordisk, KeifeRx, Eli Lilly, AriBio, Cerecin, Alzheon, Neurim Pharmaceuticals, Syneos Health, Athira Pharma, Annovis Bio, Anavex Life Sciences, AgeneBio, Eisai, among others. Agitation in Alzheimer's Disease Market Agitation in Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key agitation in Alzheimer's disease companies, including Eli Lilly and Co, BioVie Inc., AB Science SA, Annovis Bio Inc., Cognition Therapeutics Inc., Coya Therapeutics Inc., Actinogen Medical Limited, AC Immune SA, Biogen Inc., Longeveron Inc., among others. Psychosis in Parkinson's and Alzheimer's Disease Market Psychosis in Parkinson's and Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psychosis in Parkinson's and Alzheimer's disease companies, including Sunovion Pharmaceuticals, Karuna Therapeutics, Vanda Pharmaceuticals, Suven Life Sciences, Enterin, Intra-Cellular Therapies, Merck Sharp & Dohme, among others. Alzheimer's Disease Diagnostic Market Alzheimer's Disease Diagnostic Market Insights, Competitive Landscape and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key Alzheimer's disease diagnostic companies, including F. Hoffmann-La Roche Ltd., General Electric Company, 23andMe, Inc., Lilly, Fujirebio, Siemens Medical Solutions USA, Inc., Diadem srl., Todos Medical, DISCERN™, FUJIFILM Holdings America Corporation, Koninklijke Philips N.V., CANON MEDICAL SYSTEMS EUROPE B.V., Shimzadu Corporation., Laboratory Corporation of America® Holdings, Bruker, Magnetica., IMRIS, Deerfield Imaging, Inc., MR Solutions, Hyperfine, Inc., Neusoft Corporation, among others. DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Pharmaceutical Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. Connect with us at LinkedIn Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
